## RECEIVED CENTRAL FAX CENTER

MAR 3 0 2007

# Facsimile Cover Sheet For Transmission to the United States Patent and Trademark Office

	1	mark Office					
To:	U.S. Patent and Trade	U.S. Patent and Trademark Office					
	Fax. No.	(571) 273-8300					
	Application No.	10/696,464					
	Filing Date:	October 29, 2003					
	Confirmation No.:	5983 .					
	Examiner:	Celia C. Chang					
	Art Unit:	1625					
	Attorney Docket No.	P-142-US1					
From:	Theravance, Inc.						
	Attorney:	Jeffrey A. Hagenah					
	Reg. No.:	35,175					
7	Customer No.:	27038					
	Address:	901 Gateway Boulevard					
		South San Francisco, California 94080					
	Telephone No.:	(650) 808-6406					
	Fax. No.:	(650) 808-6078					
Date:	March 30, 2007	March <u>3</u> , 2007					
No. of Pages :	31 (including this pa	31 (including this page)					
	Certificate of Fa	csimile Transmission					
I hereby certify the Number (571) 27 the date indicate	nat this correspondence 73-8300 to the United Sta	is being transmitted via Facsimile ates Patent and Trademark Office, on					
Signature :	Man	Mon A. A.					
Printed Name :	Jeffrey A. Hagenah,	Jeffrey A. Hagenah, Reg. No. 35,175					

The information contained in this facsimile is intended solely for use by the United States Patent and Trademark Office. If this facsimile is received in error, please notify the sender and destroy the facsimile.

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

		Application Number	1	0/696,464	)		
TRANSMITTAL			October 29, 2003		RECEI		
FORM	Filling Date		Mammen et al.			X CENT	
. 014		First Named Inventor		625		MAR 3	<b>0</b> 2007
•		Art Unit		celia C. Char	20		
(to be used for all correspondence after i	Examiner Name			19	}		
Total Number of Pages in This Submissi	on 31	Attorney Docket Numb	oer I	P-142-US1		1	
	ENCLO	SURES (check all that ap	oply)				
Fee Transmittal Form	Drawing(	s) g-related Papers		_	ance Communication to TC	1	
Fee Attached	Licensing			Appeal Cor of Appeals	mmunication to Board and Interferences		
Amendment / Reply (29 pages)	Petition			Appeal Cor (Appeal Not	mmunication to TC lce, Brief, Reply Brief)		
After Final	Provision	o Convert to a nal Application	,- 1	Proprietary	Information		
Affidavits/declaration(s)	Power of Change	f Attorney, Revocation of Correspondence Addres	s	Status Lett	ter .		
Extension of Time Request		Disclaimer Other Enclosure(s) (please identify below):		ntify below):			
	Request for Refund			Facsimile Cov	er Page (1 page)		
Express Abandonment Request	CD, Number of CD(s)			•	•		
Information Disclosure Statement		andscape Table on CD				4	
Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application		Remarks  No fees are believed to be due for submission of this paper. However, if a fee is due, the Commissioner is authorized to charge any such fee, or to credit any overpayment, to Deposit Account No. 50-0344 (in the name of Theravance, Inc.)					
Reply to Missing Parts under 37 CFR1.52 or 1.53							
SIC	NATURE O	APPLICANT, ATTOR	NEY, OF	AGENT	<u></u>		
Firm	Theravan	Theravance, Inc.					
Signature		MARKE C					
Printed Name	leffre A.	(effre A. Hagenah				-	
Date	March 30			35,175			
	CERTIFIC	CATE OF TRANSMISSI	ON/MAI	LING	with the United States Dasts	<del></del>	
I hereby certify that this correspond Service with sufficient postage as Alexandria, VA 22313-1450 on the d	mst Gass ma	ili ili ati citionopo anaises	e USPTO	or deposited commissioner	for Patents, P.O. Box 1450	),	
Signature	1/~	44					
Typed or printed name Jeffrey	Hagenah, F	eg. No. 35,175		Date	March 30, 2007		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including participation, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Dopartment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

MAR 3 0 2007

### Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated.

Dated: March 30, 2007 Facsimile Number: (571) 273-8300

By: A. Hagehah, Reg. No. 33,175

PATENT Attorney Docket No. P-142-US1 Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re Patent Application of

MAMMEN et al.

Application No.: 10/696,464

Filed: October 29, 2003

For: SUBSTITUTED 4-AMINO-1(PYRIDYLMETHYL)PIPERIDINE

Confirmation No. 5983

Group Art Unit: 1625

Examiner: Celia C. Chang

## REPLY AND AMENDMENT PURSUANT TO 37 C.F.R. §1.111

## Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### I. INTRODUCTORY REMARKS

AND RELATED COMPOUNDS

This reply is being filed in response to the Office Action mailed on January 23, 2007, for the above-identified patent application. The Office Action set a three-month period for response and therefore, this reply is due on or before April 23, 2007. In response to the Office Action, entry of the following amendments and consideration of the following remarks is respectfully requested.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 27 of this paper.